Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT04709432
Recruiting Observational

ECMO Treatment of Children in China in the Past 10 Years

NCT04709432 · tracked via the Priya Life Science China tracker
Sponsor
Children's Hospital of Fudan University
Phase
Observational
Started
2021-01-11
Last updated
2026-03-16

Condition(s) studied

Extracorporeal Membrane OxygenationChild, Only

Investigational drug(s) / intervention(s)

ECMO

ECMO: ECMO is a form of Extracorporeal Life Support (ECLS) to support either the pulmonary, or both the pulmonary and cardiac systems.

Study summary

It is a cross-sectional study to summarize the extracorporeal membrane oxygenation （ECMO）treatment in children in China.

Eligibility

Sex
ALL
Min age
1 Day
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * age of 1d to 18 years old; * children supported by ECMO in mainland China in the past 10 years Exclusion Criteria: * none

Primary outcome measure(s)

  • survival rate — from admission to discharge （about 10days）
    survival rate after discharge

Trial sites (1)

FacilityCityRegionStatus
Children's Hospital of Fudan University Shanghai Shanghai Municipality Recruiting

More Children's Hospital of Fudan University trials in China

Neonatal Neurologic Intensive Care Network of China Recruiting
Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients Starting soon
Study on Early Genetic Screening and Precise Strategy of Neonatal Critical Illness Recruiting
Research on Circulation Management Strategy Based on Oxygen Metabolism Balance After CHD Surgery Enrolling by invitation
Clinical Features and Outcomes of CBP Versus Non-CBP in Septic Children Recruiting

Other trials for the same condition

Comparison of Stent-Related Symptoms Between Anti-Reflux Stents and Standard DJ Stents in Children With Urolithiasis Recruiting
Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO Recruiting
Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT Recruiting
Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients Recruiting
Effect of Sevoflurane on Sweat Threshold in Children of Different Ages Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04709432 on ClinicalTrials.gov ↗ ← All trials in China